ReviewAdvances in experimental medicine and biology2026
Genomic Reshuffling After Cell Fusion: Catalyst for Cancer Evolution and Progression.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fundamental relevance of cell-cell fusion processes is well studied and involves the precise spatiotemporal coordination of fusion-competent cells and the orchestration of typical fusion stages, ultimately leading to the genesis of a functional new cellular entity. While most physiological cell fusion events culminate in the formation of a multinucleated non-dividing cell, whereby nuclei remain spatially distinct, non-physiological fusion events are frequently coupled with the merging and mixing of the parental genomes. Upon cell division, fusion-induced whole-genome doubling and centrosome amplification drive chromosomal instability linked with multipolar mitoses, chromosome mis-segregation, non-disjunction and structural-associated alterations. In this context, aberrant cell fusion events can accelerate genomic heterogeneity that can potentiate the risk of cancer development and further propel cancer evolution by producing genetically diverse progeny via sub-clonal expansion. In this chapter, we provide insights into how unscheduled cell fusion events rapidly drive cancer evolution by promoting genetic and epigenetic instability, thereby creating a tumour landscape in which intratumoural heterogeneity and phenotypic plasticity increase the acquisition of traits linked with therapy resistance, stemness and immune evasion.
Indexed as
Identifiers
42168747What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.